deaths from glp-1 Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study Mapping the effectiveness and risks

Senior Litigation Counsel Jason Goldstein of Parker Waichman LLP appointed Co-Chair of the Plaintiffs Executive Committee in MDL 3163.

The GLP-1 Market size was valued at USD 52.82 billion in 2025 and is expected to grow at a CAGR of 10.9% from 2026 to 2034.

Newer agents may achieve a normal HbA1c safely and, by analogy with treatments that send cancers or inflammatory diseases into remission, this might also be considered remission

Key points from the announcement: First oral GLP-1 approved for chronic weight management Once-daily tablet (no injection) Approval based on results from the OASIS clinical program Demonstrated significant and sustained weight loss U.S

Its non stimulating nature allows flexible timing without interfering with energy levels or rest patterns

Medicare Advantage OTC (MAOTC) eligible